Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 18 to 40

LY4515100 for pain after impacted wisdom tooth removal

Official title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of a Single Oral Dose of LY4515100, in Participants Experiencing Moderate-to-Severe Acute Pain Following Surgical Removal of Impacted Third Molars

Run by Eli Lilly and Company · NCT07511816 · Data updated 2026-11-12

This trial will test whether a single oral dose of LY4515100 reduces acute pain after impacted wisdom tooth removal compared with a placebo in adults having two or more third molars removed.

Quick facts

PhasePhase 2
Study typeInterventional
Ages18 Years to 40 Years
SexAll
Enrollment212 (estimated)
SponsorEli Lilly and Company
Industry-sponsored
Locations1 site (Salt Lake City, Utah)
StatusRecruiting
StartedApril 1, 2026
Main results expectedNovember 2026
Study endsDecember 2026
Registry record updatedMay 1, 2026
Trial IDNCT07511816 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults scheduled for extraction of two or more third molars (including two impacted lower molars), with BMI between 18.5 and 35 and no recent dental surgery or chronic pain conditions.

Probably not a fit

Patients with chronic pain conditions, recent dental surgery, positive drug or alcohol screens, significant recent medical illnesses, or recent history of treated malignancy are unlikely to be eligible or to receive benefit from this trial.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults who require extraction of two or more third molars, including two mandibular molars with partial or full bony impaction, are enrolled and must meet BMI and screening criteria. After impacted third molar removal, participants remain in a clinical research unit and receive a single oral dose of LY4515100 or placebo, with close monitoring for pain relief and safety. The study follows participants for roughly six weeks to collect acute pain outcomes and monitor adverse events. Screening includes urine drug and alcohol testing and medical history review to minimize confounding factors.

Why it matters

Potential benefit: If successful, LY4515100 could offer effective single-dose relief for acute pain after wisdom tooth extraction.

How similar studies have gone: Single-dose oral analgesics have proven effective for post–third molar pain in prior studies, but LY4515100 itself is being tested in this Phase 2 trial.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participant has a body mass index (BMI) between 18.5 and 35.0 kilograms per meter squared (kg/m²) inclusive.
* Participant requires extraction of 2 or more third molars, including 2 mandibular molars with partial or full bony impaction, confirmed by panoramic X-ray.

Exclusion Criteria:

* Prior dental surgery within 60 days before screening or history of other surgical procedures that could confound surgery or postoperative procedures.
* Diagnosis of chronic pain conditions that could confound postsurgical pain reporting in the opinion of the investigator.
* Positive urine drug screen or alcohol test during screening or on the day of surgery.
* Evidence or history of any other clinically significant hematological, renal, hepatic, endocrine, pulmonary, gastrointestinal, cardiovascular, psychiatric, or neurologic diseases, in the opinion of the investigator, within the last 5 years.
* History of malignancy of any organ system treated or untreated, within 5 years prior to consent. The only exceptions are previous in situ carcinoma of the cervix, localized basal cell carcinoma of the skin, or localized squamous carcinoma of the skin if the participant has been treated and is considered cured.

Where it's running

  • JBR Clinical Research
    Salt Lake City, Utah, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.